Targeted Gene Delivery 2.0: Next-Generation Self-Replicating Cell Selective Gene Delivery

A paradigm-shifting gene delivery system that leverages self-replicating cells, microRNA target sequences, and nanoparticles for targeted and personalized therapy, enabling unprecedented precision and efficacy in treating diseases.

Despite the progress in gene therapy, current approaches often suffer from lack of specificity, limited efficacy, and unwanted side effects. The original patent's self-replicating cell selective gene delivery compositions, methods, and uses thereof, while groundbreaking, have limitations in terms of targeting and delivery. The new inventive concept addresses these limitations by introducing a more sophisticated and adaptable system that can selectively target specific cell subsets and deliver therapeutic proteins with unprecedented precision.

The next-generation gene delivery system comprises a self-replicating cell, a gene of interest, and a microRNA target sequence specifically designed to target a subset of cells expressing a specific marker. The system can be administered to a subject, where the composition selectively delivers the therapeutic protein to the targeted cells. The system can be further enhanced by incorporating nanoparticles for targeted delivery and diagnostic tools for identifying the specific marker in the subset of cells. This enables personalized gene therapy and unprecedented precision in treating diseases.

The new claims introduce a novel combination of self-replicating cells, microRNA target sequences, and nanoparticles, which provides a significant improvement over the original patent. The inventive step lies in the specific design of the microRNA target sequence to target specific cell subsets, the use of nanoparticles for targeted delivery, and the integration of diagnostic tools for personalized gene therapy.

Alternative embodiments of the inventive concept could include the use of different types of self-replicating cells, various microRNA target sequences, and different nanoparticle formulations. Additionally, the system could be adapted for use in different disease indications, such as cancer, genetic disorders, or infectious diseases.

The targeted gene delivery system has vast commercial potential in the gene therapy market, which is projected to reach $10 billion by 2025. The system's ability to provide personalized and targeted therapy could revolutionize the treatment of diseases, making it an attractive solution for pharmaceutical companies, biotech firms, and research institutions.